BCR/ABL1 Tyrosine kinase inhibitor mutation screen

Alphabetical Test listing

BCR/ABL1 Tyrosine kinase inhibitor mutation screen-994

BCR/ABL1 Tyrosine kinase inhibitor mutation screen
TKI resistance
  • Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment
  • Preferred initial test to identify the presence of acquired BCR-ABL1 mutations associated with TKI-resistance


EDTA whole blood
10 mL
4 mL

Lavender (EDTA), 10mL

Bone marrow
4.0mL (minimum 2 mL)

Lavender (EDTA), 4mL

  • Patient's fusion type (p210, p190, p205 or p230)
  • Pertinent clinical history
  • Clinical or morphologic suspicion
  • Date of collection
  • Specimen source (blood or bone marrow)

Molecular Medicare billing request

  • Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
  • All information requested is required in order for your request to be completed

Refrigerated (preferred) - 5 days
Ambient - 72 hours

Mayo Clinic Laboratories (BAKDM): R-NX
Mo - Fr
5 days

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Analysis of PCR Products by Sanger Sequencing


An interpretive report will be provided

This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.